Nektar Therapeutics (NKTR) Price & Analysis

Compare

1,561 Followers

NKTR Stock Chart & Stats

$57.74

-$0.04(-3.36%)

At close: Jan 08 4:00 PM EST

$57.74

-$0.04(-3.36%)

Day’s Range― - ―

52-Week Range$6.49 - $66.92

Previous CloseN/A

Volume706.47K

Average Volume (3M)626.41K

Market Cap

$1.20B

Enterprise Value$974.93M

Total Cash (Recent Filing)$270.21M

Total Debt (Recent Filing)$91.92M

Price to Earnings (P/E)―

Beta4.13

Next Earnings

Mar 04, 2026

EPS Estimate

-2.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.87

Shares Outstanding20,341,589

10 Day Avg. Volume479,607

30 Day Avg. Volume626,410

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)3.15

Price to Sales (P/S)1.94

P/FCF Ratio-1.08

Enterprise Value/Market Cap0.82

Enterprise Value/Revenue15.57

Enterprise Value/Gross Profit17.85

Enterprise Value/Ebitda-11.26

Forecast

1Y Price Target

$97.63

Price Target Upside69.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)-9.99

Revenue Forecast (FY)$42.18M

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentManagement believes it is well on track to initiate a phase III trial for rezpeg in atopic dermatitis.

Market PositionRezpeg could become a best-in-disease therapy for severe and potentially moderate alopecia areata patients.

Therapeutic PotentialRezpeg achieved statistical significance on the primary endpoint and all key secondary endpoints, indicating its strong therapeutic potential.

Bears Say

Adverse ReactionsThe high frequencies (about 30%) of injection site reactions with moderate severity could be a commercial liability for rezpeg.

Market CompetitionRezpeg is not expected to displace Dupixent as the main front-line biologic in atopic dermatitis.

Market ValuationEven with optimistic assumptions, the valuation could still be below the current stock price.

Nektar Therapeutics News

Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

16d ago

Nektar price target raised to $121 from $99 at Jefferies

Jefferies raised the firm’s price target on Nektar (NKTR) to $121 from $99 and keeps a Buy rating...

16d ago

NKTR

Citi starts Nektar with Buy, opens ‘positive catalyst watch’

Citi initiated coverage of Nektar (NKTR) with a Buy rating and $102 price target Citi also opened a...

16d ago

NKTR

Nektar files automatic mixed securities shelf

16:09 EST Nektar (NKTR) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

30d ago

NKTR

Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($CTRA) ), ( ($OVV) ), ( ($NKTR) ), ( ($CODX)...

13d ago

OVV

CODX

Nektar Therapeutics Announces Chief Legal Officer Departure

Nektar Therapeutics ( ($NKTR) ) has issued an announcement. On November 21, 2025, Nektar Therapeutics announced the departure...

21d ago

NKTR

Hold Rating Maintained Amid Uncertainty in Rezpeg Trial Outcomes and Ongoing Research

William Blair analyst Andy Hsieh has maintained their neutral stance on NKTR stock, giving a Hold rating on...

25d ago

NKTR

Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment

Analyst Julian Harrison of BTIG maintained a Buy rating on Nektar Therapeutics, retaining the price target of $100.00....

27d ago

NKTR

Nektar Therapeutics Reveals Promising Phase 2b Trial Results

Nektar Therapeutics ( ($NKTR) ) has provided an update. On November 8, 2025, Nektar Therapeutics presented new data...

1M ago

NKTR

Nektar presents new data from REZOLVE-AD study of ACAAI

Nektar (NKTR) Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract...

1M ago

NKTR

Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation

Nektar Therapeutics (($NKTR)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

NKTR

Nektar Therapeutics Reports Q3 2025 Financial Results

Nektar Therapeutics ( ($NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar...

1M ago

NKTR

Hold Rating on Nektar Therapeutics Amid Uncertainties in Rezpeg’s Clinical Trials and Market Potential

William Blair analyst Andy Hsieh has reiterated their neutral stance on NKTR stock, giving a Hold rating on...

1M ago

NKTR

Nektar reports Q3 adjusted EPS ($1.85), consensus ($2.79)

Reports Q3 revenue $11.8M, consensus $10.2M. “We have made tremendous progress advancing rezpegaldesleukin, and the emerging data from...

1M ago

NKTR

NKTR FAQ

What was Nektar Therapeutics’s price range in the past 12 months?

Nektar Therapeutics lowest stock price was $6.49 and its highest was $66.92 in the past 12 months.

What is Nektar Therapeutics’s market cap?

Nektar Therapeutics’s market cap is $1.20B.

When is Nektar Therapeutics’s upcoming earnings report date?

Nektar Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 82 days.

How were Nektar Therapeutics’s earnings last quarter?

Nektar Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.685 by $0.815.

Is Nektar Therapeutics overvalued?

According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nektar Therapeutics pay dividends?

Nektar Therapeutics does not currently pay dividends.

What is Nektar Therapeutics’s EPS estimate?

Nektar Therapeutics’s EPS estimate is -2.42.

How many shares outstanding does Nektar Therapeutics have?

Nektar Therapeutics has 20,341,589 shares outstanding.

What happened to Nektar Therapeutics’s price movement after its last earnings report?

Nektar Therapeutics reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.685. Following the earnings report the stock price went up 1.542%.

Which hedge fund is a major shareholder of Nektar Therapeutics?

Currently, no hedge funds are holding shares in NKTR

Nektar Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-180.24%

Trailing 12-Months

Asset Growth

-2.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nektar Therapeutics

Nektar Therapeutics (NKTR) is a biopharmaceutical company focused on discovering and developing innovative therapeutics to treat chronic and life-threatening diseases. The company primarily operates in the biopharmaceutical sector, concentrating on areas such as oncology, immunology, and pain management. Nektar's core products include its proprietary drug candidates that utilize its advanced drug delivery technology, which enhances the therapeutic effect and reduces side effects of treatments.

Nektar Therapeutics (NKTR) Earnings & Revenues

Historic Earnings Reports

NKTR Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented strong financial health, significant progress in clinical trials, and recognition for their scientific contributions. The challenges with existing treatments in alopecia areata were acknowledged but present an opportunity for REZPEG to fill a critical need.View all NKTR earnings summaries

NKTR Stock 12 Month Forecast

Average Price Target

$97.63

▲(69.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","65":"$65","122":"$122","36.5":"$36.5","93.5":"$93.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,36.5,65,93.5,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,65.71692307692308,70.32384615384615,74.93076923076923,79.53769230769231,84.14461538461538,88.75153846153846,93.35846153846154,97.96538461538461,102.57230769230769,107.17923076923077,111.78615384615384,116.39307692307692,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,63.919230769230765,66.72846153846153,69.53769230769231,72.34692307692308,75.15615384615384,77.96538461538461,80.77461538461537,83.58384615384615,86.39307692307692,89.20230769230768,92.01153846153846,94.82076923076923,{"y":97.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,58.716923076923074,56.323846153846155,53.93076923076923,51.53769230769231,49.144615384615385,46.75153846153846,44.35846153846154,41.965384615384615,39.57230769230769,37.17923076923077,34.786153846153844,32.39307692307692,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >